Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
Chemodex
Caroverin
Product Details | |
---|---|
Synonyms | 1-[2-(Diethylamino)ethyl]-3-(p-methoxybenzyl)-2-quinoxalone; Spadon; Spasmium |
Product Type | Chemical |
Properties | |
Formula | C22H27N3O2 |
MW | 365.47 |
CAS | 23465-76-1 |
Source/Host Chemicals | Synthetic. |
Purity Chemicals | ≥99% (HPLC) |
Appearance | White or slightly yellow, fine powder. |
Solubility | Soluble in DMSO (10 mg/ml). Insolube in water. |
Identity | Determined by NMR. |
Declaration | Manufactured by Chemodex. |
Other Product Data |
Click here for Original Manufacturer Product Datasheet |
InChi Key | MSPRUJDUTKRMLM-UHFFFAOYSA-N |
Smiles | O=C1N(CCN(CC)CC)C2=C(C=CC=C2)N=C1CC3=CC=C(OC)C=C3 |
Shipping and Handling | |
Shipping | AMBIENT |
Short Term Storage | +20°C |
Long Term Storage | +4°C |
Handling Advice |
Keep cool and dry. Protect from light and moisture. |
Use/Stability | Stable for at least 2 years after receipt when stored at +4°C. |
Documents | |
MSDS | Inquire |
Product Specification Sheet | |
Datasheet | Download PDF |
Quinoxaline compound, originally developed as a spasmolytic drug. Acts as an N-type calcium channel blocker, competitive AMPA receptor antagonist, and non-competitive NMDA receptor antagonist. Antioxidant agent through partial prevention of the formation and the highly active scavenging of hydroxyl radicals. Used to treat inner ear diseases such as tinnitus. Shown to inhibit tumor-promoting factors and potentially useful as a chemotherapeutic agent.
(1) Y. Ishida, et al., Br. J. Pharmacol. 71, 343 (1980) | (2) B. Saletu, et al.; Arzneimittelforsch. 45, 217 (1995) | (3) D.M. Denk, et al.; Acta Otolaryngol. 117, 825 (1997) | (4) H. Nohl, et al.; Biofactors 19, 79 (2003) | (5) G. Haymerle, et al.; Eur. Arch. Otorhinolaryngol. 272, 3451 (2015)